Next-Generation Psychedelics

Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
Fed Agency Grants $14M To Gilgamesh For Cardiac-Safe Ibogaine Analog Targeting Opioid Use Disorder
Cybin's Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What's Next?
Fed Agency Grants $14M To Gilgamesh For Cardiac-Safe Ibogaine Analog Targeting Opioid Use Disorder
Cybin's Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What's Next?
Clearmind Medicine's Reverse Stock Split And Nasdaq Delisting Notice
Enveric Biosciences' Revenue Drops In Q3 2023 As Next-Gen Psychedelics Advance To Clinical Trials

Next-Generation Psychedelics Recent News

Johns Hopkins Will Work With Clearmind On Alcohol Addiction Research Program
Israeli psychedelics biotech Clearmind Medicine (NASDAQ: CMND) has inked a research agreement with Johns Hopkins University School of Medicine (JHU) to conduct the first-in-human Phase I/IIa clinical trial on its proprietary MEAI-based compound CMND-100 for the potential treatment of Alcoho
Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement by which Otsuka America Inc., the U.S. arm of Otsuka Pharmaceutical Co., would acquire all its outstanding shares in an all-cash transaction for approximately $60 (CA$80) million.
Boosting Next-Gen Mental Health Care: Enveric's New US Patent For Anxiety Treatment
The USPTO issued a patent covering Enveric Biosciences’ (NASDAQ: ENVB) lead candidate EB-373, a psilocin prodrug under development for the treatment of anxiety disorder.
Psychedelics IP Protection: Cybin Nabs US Patent For Deuterated Analogs, Psilera Advances Next-Gen Library
Cybin’s New US Patent Covers Proprietary Deuterated Psychedelic Analogs
Enveric's Q2 2023 Financials Show Immediate Need For Budget-Slimming Toward A Clinical-Staged 2024
Next-gen psychedelics business Enveric Biosciences (NASDAQ: ENVB) reported its unaudited financial results for the second quarter of 2023 ended June 30. Results show:
Bright Mind Shares Surge 91% After Reporting Positive EEG Clinical Results Of Next-Gen Compound
After Bright Minds Bioscience's (NASDAQ: DRUG) announcement that its quantitative EEG garnered positive results, the company stock shot up 91% Tuesday morning,  spiking to $6.18 from Monday's close of $3.23 per share.
Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details
Clinical-stage psychedelics biotech Reunion Neuroscience (NASDAQ: REUN) and MPM BioImpact have completed their announced plan of arrangement for MPM&rsq
Terran Biosciences Steps Into 4-OH-DiPT Prodrug Arena With New Patent Application
As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also filed a patent application over a proprietary polymorph, 
Reunion Neuroscience On The Brink Of Going Private With Final Court Approval
Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution approving the proposed arrangement plan on July 12.
Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research
MAPS recent Psychedelic Science 2023 conference hosted a discussion on the newly-synthesized compounds by the organization, which is advancing the legacy of the renowned chemist Alexander
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical study on proprietary psilocin analog L-130. 
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
Psychedelics biotech BetterLife Pharma Inc. (OTCQB: BETRF) is fast-tracking its U.S.
Cybin's FY2023 Financials, Guidance And Appointment Of Sanford R. Climan As Strategic Advisor
Psychedelics biopharma company Cybin Inc. (NYSE: CYBN) shared its financial results for the fiscal year ended this March 31 as well as recent business highlights. Numbers show: Total cash of $12.5 (CA$16.6) million by March 31, 2023.
UK Greenlights Phase 2 Clinical Trial On Mindset Pharma's Psilocin Drug For Major Depression
Drug discovery company Mindset Pharma (OTCQB: MSSTF) received approval from the U.K.
Canadian Financing: PharmAla Biotech Offers Non-Brokered Private Placement Up To $3.76M
MDXX-class molecules biotech company PharmAla Biotech Holdings Inc. (OTCMKTS: PMBHF) has announced a non-brokered private placement of a minimum of 3.3 million units and a maximum of 16.6 million of its units at a price of $0.22 (CA$0.30) each, corresponding to aggregate gross proceeds of minimum $752,300 (CA$1 million,) and maximum $3.76 (CA$5 million.) 
Mydecine's Prospectus Supplement Closing Under Share Subscription And Management Update
Colorado-based next-generation psychedelics biotech Mydecine Innovations Group Inc. (OTC: MYCOF) announced that, in connection with its common share subscription agreement with a third-party investor dated this past March 10, it has filed a shelf prospectus supplement to its final base shelf prospectus for th
This Company's Psilocybin-Based Non Hallucinogenic Compound Heads Toward Clinical Studies
Biopharma company Psilera Inc. announced it has selected its first clinical candidate, a novel drug sharing several of psilocybin’s properties but without the hallucinogenic effects.
Promising Multiple Sclerosis Drug Candidate Advances: First Clinical Trial Dosing Completed
FSD Pharma Inc. (NASDAQ: HUGE), a biopharma company developing innovative assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, announced the first cohort of participants on its
Delix's Non-Hallucinogenic Psychoplastogen Enters Phase 1 Trial
Delix Therapeutics, a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, received regulatory approval and is set to commence recruitment for a Phase 1 clinical trial on its non-hallucinogenic psychoplastogen lead drug candidate, DLX-001.
NY Biotech Gets International IP Coverage For Growing Portfolio Of Psychedelic-Derived Novel Drugs
New York-based therapeutics biotech platform Terran Biosciences published a new World International Patent Organization (WIPO) application under the Patent Cooperation Treaty (PCT) to protect its novel, non-hallucinogenic psychoplastog
This Firm Bets On Non-Hallucinogenic Psychedelics, Files Claims For International IP Protection
Numerous biopharma companies are working on enhancing first-generation or “classical” psychedelics. They're tuning down the side effects, and protecting their findings along the way.
Stress, Anxiety, PTSD: 2 NASDAQ-Listed Drug Developers Advance Psychedelic-Inspired Meds
Psychedelics biotech Silo Pharma Inc. (NASDAQ: SILO) and Columbia University are developing a novel compound formulation as a prophylactic treatment for stress, anxiety and PTSD.
Are Next-Gen Psychedelics The Incoming Solution For Mental Health? Learn It All At Benzinga's Psychedelics Capital Conference
Since the beginning of the new wave in medicine and public opinion, there has been a retaking of psychedelics-assisted therapy for the treatment of mental health conditions commonly known as Psychedelics Renaiss